Erythropoietin, a treatment for newborns with critically low levels of oxygen or blood supply to the brain at birth, does not prevent death or disability, according to a new multinational study. The research was presented at the Pediatric Academic Societies (PAS) 2025 Meeting, held April 24–28 in Honolulu.